It's fun to speculate but you can lose faith and sell at the wrong time. I think this co is set up nicely for the next 5 years. If we get positive data on multiple P2 trials along with Polystart moving out of preclinical into a P1 this could be the lottery for many. AZN is just the beginning of TPIV getting on the radar of BP. It's still my guess and I stress "guess" that ROCHE will eventually buy the company out. But if these trials show great data money will flow in through licensing agreements and they could go it alone. Not sure if that's the strategy Glynn wants to take. I think he'd sell for the right price. Right now that would be miniscule compared to 3 years from now with proven data. 3 years will fly by if one isn't watching day to day price action. JMHO
News 
Market Data 
Discover 
